Aprea to present at the American Association for Cancer Research (AACR) annual meeting in Washington, DC, in April 2013
STOCKHOLM – April 3, 2013. Aprea AB today announces that a poster entitled “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients” will be presented at the upcoming AACR meeting in Washington, DC, USA, in April 2013. Aprea is a Karolinska Development portfolio company.
The poster contains data from preclinical combination studies with APR-246 and platinum compounds. The presentation will take place on Tuesday April 9 between 8.00 AM and 12.00 PM (EST) at the AACR meeting at the Walter E. Washington Convention Center, in the session Experimental and Molecular Therapeutics. The presentation will be held by Dr. Nina Mohell. The abstract (Abstract # 3448) is available on AACR’s website, www.aacr.org.
For further information, please contact:
Ulf Björklund, CEO, Aprea AB
Phone: +46 (0)8 508 845 04, e-mail: firstname.lastname@example.org
TO THE EDITORS
Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Östersjöstiftelsen, Praktikerinvest and KCIF Co-Investment Fund KB. For more information, please visit www.aprea.com.
APR-246 has been developed based on results from researchers at Karolinska Institutet, and has been shown to reactivate the non-functional tumor suppressor protein p53 and induce programmed cell death in many human cancer cells. Aberrations in p53 are common in many cancer forms and are associated with increased resistance to standard chemotherapy resulting in a poor prognosis. For these patients no treatment other than palliative care exists. In preclinical studies APR-246 has demonstrated unique pharmacological properties as compared to conventional chemotherapy, by being effective also in cancer cells with p53 mutations and by preferentially targeting tumor cells over normal cells. A clinical phase I/II study on hematological malignancies and prostate cancer with APR-246 has been completed with promising results. It had a good safety profile and both biological and clinical responses were observed. A Phase II Proof of Concept study in ovarian cancer patients carrying mutant p53 is currently being prepared.